Sanofi India Ltd

Sanofi Healthcare India Private Limited acquired 3,500,000 equity shares, representing 15.20% of the equity share capital, from Hoechst GmbH on September 24, 2026, through a block deal mechanism. The acquisition, an inter-se transfer among promoter and promoter group members of Sanofi India Limited, maintains the aggregate holding of the promoter group unchanged. Sanofi Healthcare India Private Limited was exempted from making an open offer under Regulation 10(1)(a)(iii) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and previously disclosed the transaction on September 17, 2026.

Sanofi India Limited will close its trading window from October 1, 2026, until 48 hours after the announcement of its unaudited financial results for the quarter and nine months ending September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Sanofi India Limited reported a net profit of Rs 1,861 million for the half-year ended June 30, 2026, a slight decrease from Rs 1,890 million in the same period last year. While the company’s profit before tax declined by Rs 92 million, representing a 3.56% decrease, the company’s total assets increased to Rs 14,074 million from Rs 12,548 million. The company’s total equity also rose to Rs 8,260 million from Rs 7,492 million. Sanofi India experienced a net cash inflow of Rs 2,114 million from operating activities and a net increase in cash and cash equivalents of Rs 961 million, alongside a substantial dividend payment. The increase in trade receivables and inventory warrants further monitoring, and a prior year personnel separation cost of Rs 273 million impacted previous results.

Sanofi India Limited announced that Mr. Nakul Verma, Head of Public Affairs & Market Access, will cease to be a Senior Management Personnel with effect from the close of business hours on 31st July 2026, due to a transition to another role within the Sanofi group.

The company said Ayari has decided to relinquish his current responsibilities following his transition to another role within the Sanofi group. Following his cessation, Ayari will no longer serve as Whole Time Director, CFO, KMP, Senior Management Personnel, or a member of the Risk Management Committee of the company. Sanofi India expressed its appreciation for Ayari's contributions, expert guidance, and support during his tenure with the company. The company is currently in the process of identifying a suitable candidate for the position of Chief Financial Officer, who will also be appointed as a Key Managerial Personnel. The company will make an announcement regarding the appointment in due course. Sanofi India is engaged in the manufacture and marketing of pharmaceutical products and vaccines. On a standalone basis, Sanofi India's net profit declined 14.14% to Rs 102.60 crore while net sales declined 11.87% to Rs 472.30 crore in Q4 March 2026 over Q4 March 2025. The scrip shed 0.33% to Rs 3,392.40 on the BSE. Powered by Capital Market - Live

Sanofi India will hold a meeting of the Board of Directors of the Company on 4 August 2026.

According to exchange data, Nippon India Mutual Fund purchased 2.64 lakh shares, or 1.15% equity, of Sanofi India at Rs 3,150 per share through a bulk deal on 12 June 2026. The shares were sold by HDFC Life Insurance Company, which offloaded 2.75 lakh shares, or 1.19% equity, at the same price. As of the March 2026 quarter, Nippon India Small Cap Fund held an aggregate 3.79% stake in Sanofi India, while HDFC Life Insurance Company's Shareholders Solvency Margin Account owned 1.47% of the pharmaceutical company. Sanofi India is engaged in the manufacture and marketing of pharmaceutical products and vaccines. On a standalone basis, Sanofi India's net profit declined 14.14% to Rs 102.60 crore while net sales declined 11.87% to Rs 472.30 crore in Q4 March 2026 over Q4 March 2025. Powered by Capital Market - Live

Sanofi India announced the appointment of Debajit Roy as Sales & Customer Engagement Head ' Diabetes, designated as Senior Management Personnel of the Company with effect from 8 June 2026.

Net profit of Sanofi India declined 14.14% to Rs 102.60 crore in the quarter ended March 2026 as against Rs 119.50 crore during the previous quarter ended March 2025. Sales declined 11.87% to Rs 472.30 crore in the quarter ended March 2026 as against Rs 535.90 crore during the previous quarter ended March 2025. ParticularsQuarter EndedMar. 2026Mar. 2025% Var. Sales472.30535.90 -12 OPM %30.2432.08 - PBDT146.90174.90 -16 PBT137.90165.30 -17 NP102.60119.50 -14 Powered by Capital Market - Live

Sanofi India will hold a meeting of the Board of Directors of the Company on 28 April 2026.